Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...

We tested adult diapers in our labs and got feedback from regular users to find the very best adult diapers and incontinence ...

In this new leadership role, Owen Plietz will oversee hospital operations, pharmacy services, nursing, continuum of care and ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

Analysts are largely maintaining a "Hold" stance for now. The consensus average price target of $44.90 implies potential upside, but experts appear to be taking a wait-and-see approach. The key ...

At an FDA discussion of testosterone replacement therapy, a top official called for special health centers to address a ...

Delving into the details, we found 53% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $373,316, and 7 were calls, valued ...

Women are healthcare’s power users yet face diagnostic delays, higher dismissal rates, and AI bias. New innovators aim to ...

No financial data available at this time. Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will ...